WebAug 31, 2024 · FORT COLLINS, Colo., Aug. 31, 2024 — Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that … WebSep 7, 2024 · Cytocom acquired ImQuest Life Science, Inc. in an all-stock deal on June 23, 2024, and provided an update on its integration on September 1. Together, these entities will strengthen and expand...
Cytocom, Inc. Announces Plan to Adopt New Corporate Name …
WebUntil the transaction is completed, Cytocom (now, Statera Biopharma, Inc.) does not have a clear title and interest to our Company’s technology. In March 2024, the Company and Cytocom negotiated an amendment to the licensing agreement (“Third License Amendment”) which has been submitted to the board of directors of Cytocom for approval. WebMay 13, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers ... phillip lewis attorney
VA Enterprise Information Management (EIM) Policy
WebSep 14, 2024 · Originator Cytocom Developer Statera BioPharma Class Small molecules Mechanism of Action Immunomodulators Orphan Drug Status No New Molecular Entity Yes Highest Development Phases Phase I Fibromyalgia Most Recent Events 14 Sep 2024 Statera Biopharma plans a clinical trial for Fibromyalgia, in 2024 (Statera Biopharma … WebStatera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. phillip liebel